- call +1-201-465-4211
- email sales@mrinsights.biz
Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal with injury or infection. Increasing levels of cortisol increases the blood sugar and can even cause diabetes mellitus. However the disease is also caused due to excess production of hypothalamus corticotropin releasing hormone (CRH) which stimulates the synthesis of cortisol by the adrenal glands.
Scope of the Report:
This report studies the Cushing’s Disease Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cushing’s Disease Treatment market by product type and applications/end industries.
Cushing’s disease treatment market revenue is growing with a stable growth rate, this is attributed to increasing number of pipeline drugs. Also increasing interest of pharmaceutical companies to develop Cushing disease drugs is a major factor contributing to the revenue growth of Cushing disease treatment market over the forecast period. Current and emerging players’ focuses on physician education and awareness regarding availability of different drugs for curing Cushing disease, thus increasing the referral speeds, time to diagnosis and volume of diagnosed Cushing disease individuals. Growing healthcare expenditure and increasing awareness regarding Cushing syndrome aids in the revenue growth of Cushing’s disease treatment market. Increasing number of new product launches also drives the market for Cushing’s disease Treatment devices. However availability of alternative therapies for curing Cushing syndrome is expected to hamper the growth of the Cushing’s disease treatment market over the forecast period.
The global Cushing’s Disease Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cushing’s Disease Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
CORCEPT THERAPEUTICS
HRA Pharma
Strongbridge Biopharma
Novartis
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Ketoconazole
Mitotane
Aminoglutethimide
Metyrapone
Mifepristone
Etomidate
Pasireotide
Market Segment by Applications, can be divided into
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Clinics
E-Commerce/Online Pharmacies
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Cushing’s Disease Treatment Market Overview
1.1 Product Overview and Scope of Cushing’s Disease Treatment
1.2 Classification of Cushing’s Disease Treatment by Types
1.2.1 Global Cushing’s Disease Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Cushing’s Disease Treatment Revenue Market Share by Types in 2017
1.2.3 Ketoconazole
1.2.4 Mitotane
1.2.5 Aminoglutethimide
1.2.6 Metyrapone
1.2.7 Mifepristone
1.2.8 Etomidate
1.2.9 Pasireotide
1.3 Global Cushing’s Disease Treatment Market by Application
1.3.1 Global Cushing’s Disease Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Drug Stores
1.3.5 Clinics
1.3.6 E-Commerce/Online Pharmacies
1.4 Global Cushing’s Disease Treatment Market by Regions
1.4.1 Global Cushing’s Disease Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Cushing’s Disease Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Cushing’s Disease Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Cushing’s Disease Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Cushing’s Disease Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Cushing’s Disease Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Cushing’s Disease Treatment (2013-2023)
2 Manufacturers Profiles
2.1 CORCEPT THERAPEUTICS
2.1.1 Business Overview
2.1.2 Cushing’s Disease Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 CORCEPT THERAPEUTICS Cushing’s Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 HRA Pharma
2.2.1 Business Overview
2.2.2 Cushing’s Disease Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 HRA Pharma Cushing’s Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 Strongbridge Biopharma
2.3.1 Business Overview
2.3.2 Cushing’s Disease Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Strongbridge Biopharma Cushing’s Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis
2.4.1 Business Overview
2.4.2 Cushing’s Disease Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis Cushing’s Disease Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cushing’s Disease Treatment Market Competition, by Players
3.1 Global Cushing’s Disease Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Cushing’s Disease Treatment Players Market Share
3.2.2 Top 10 Cushing’s Disease Treatment Players Market Share
3.3 Market Competition Trend
4 Global Cushing’s Disease Treatment Market Size by Regions
4.1 Global Cushing’s Disease Treatment Revenue and Market Share by Regions
4.2 North America Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
5 North America Cushing’s Disease Treatment Revenue by Countries
5.1 North America Cushing’s Disease Treatment Revenue by Countries (2013-2018)
5.2 USA Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
6 Europe Cushing’s Disease Treatment Revenue by Countries
6.1 Europe Cushing’s Disease Treatment Revenue by Countries (2013-2018)
6.2 Germany Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
6.4 France Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Cushing’s Disease Treatment Revenue by Countries
7.1 Asia-Pacific Cushing’s Disease Treatment Revenue by Countries (2013-2018)
7.2 China Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
7.5 India Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
8 South America Cushing’s Disease Treatment Revenue by Countries
8.1 South America Cushing’s Disease Treatment Revenue by Countries (2013-2018)
8.2 Brazil Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Cushing’s Disease Treatment by Countries
9.1 Middle East and Africa Cushing’s Disease Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Cushing’s Disease Treatment Revenue and Growth Rate (2013-2018)
10 Global Cushing’s Disease Treatment Market Segment by Type
10.1 Global Cushing’s Disease Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Cushing’s Disease Treatment Market Forecast by Type (2018-2023)
10.3 Ketoconazole Revenue Growth Rate (2013-2023)
10.4 Mitotane Revenue Growth Rate (2013-2023)
10.5 Aminoglutethimide Revenue Growth Rate (2013-2023)
10.6 Metyrapone Revenue Growth Rate (2013-2023)
10.7 Mifepristone Revenue Growth Rate (2013-2023)
10.8 Etomidate Revenue Growth Rate (2013-2023)
10.9 Pasireotide Revenue Growth Rate (2013-2023)
11 Global Cushing’s Disease Treatment Market Segment by Application
11.1 Global Cushing’s Disease Treatment Revenue Market Share by Application (2013-2018)
11.2 Cushing’s Disease Treatment Market Forecast by Application (2018-2023)
11.3 Hospital Pharmacies Revenue Growth (2013-2018)
11.4 Retail Pharmacies Revenue Growth (2013-2018)
11.5 Drug Stores Revenue Growth (2013-2018)
11.6 Clinics Revenue Growth (2013-2018)
11.7 E-Commerce/Online Pharmacies Revenue Growth (2013-2018)
12 Global Cushing’s Disease Treatment Market Size Forecast (2018-2023)
12.1 Global Cushing’s Disease Treatment Market Size Forecast (2018-2023)
12.2 Global Cushing’s Disease Treatment Market Forecast by Regions (2018-2023)
12.3 North America Cushing’s Disease Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Cushing’s Disease Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Cushing’s Disease Treatment Revenue Market Forecast (2018-2023)
12.6 South America Cushing’s Disease Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Cushing’s Disease Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Cushing’s Disease Treatment Picture
Table Product Specifications of Cushing’s Disease Treatment
Table Global Cushing’s Disease Treatment and Revenue (Million U
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
